CAS 1434635-54-7

ND-630

CAS: 1434635-54-7

Fórmula: C₂₈H₃₁N₃O₈S

Pureza: 97%

Forma y color: Solid

Peso molecular: 569.6260

Ref: IN-DA01EN4Y

Firsocostat

CAS: 1434635-54-7

Firsocostat

Pureza: ≥98%

Peso molecular: 569.63g/mol

Ref: 54-BUP12282

(R)-2-(1-(2-(2-Methoxyphenyl)-2-((Tetrahydro-2H-Pyran-4-Yl)Oxy)Ethyl)-5-Methyl-6-(Oxazol-2-Yl)-2,4-Dioxo-1,4-Dihydrothieno[2,3-d]Pyrimidin-3(2H)-Yl)-2-Methylpropanoic Acid

CAS: 1434635-54-7

(R)-2-(1-(2-(2-Methoxyphenyl)-2-((Tetrahydro-2H-Pyran-4-Yl)Oxy)Ethyl)-5-Methyl-6-(Oxazol-2-Yl)-2,4-Dioxo-1,4-Dihydrothieno[2,3-d]Pyrimidin-3(2H)-Yl)-2-Methylpropanoic Acid

Pureza: 97%

Peso molecular: 569.63g/mol

Ref: 54-OR1024205

Firsocostat

CAS: 1434635-54-7

Fórmula: C₂₈H₃₁N₃O₈S

Peso molecular: 569.63

Ref: 4Z-F-199001

Firsocostat-13C-d3

CAS: 1434635-54-7

Fórmula: C₂₇₁₃CH₂₈D₃N₃O₈S

Peso molecular: 573.64

Ref: 4Z-F-199002

Firsocostat

CAS: 1434635-54-7

Firsocostat (GS-0976) is an inhibitor of acetyl-CoA carboxylase (ACC) dimerization that inhibits human ACC1 and ACC2 activity (IC50s of 2.1 and 6.1 nM).

Fórmula: C₂₈H₃₁N₃O₈S

Pureza: 98% - 98.46%

Forma y color: Solid

Peso molecular: 569.63

Ref: TM-T7184

ND-630

CAS: 1434635-54-7

ND-630 is a drug that has been designed to treat metabolic disorders by targeting the transcription-polymerase chain reaction of the epidermal growth factor. It has been shown to alleviate liver lesions and hepatic steatosis in mice. ND-630 may also be a potential biomarker for hepatocyte injury, as it has been shown to have an effect on energy metabolism and lipid synthesis. There is also some evidence that ND-630 may be used as an anthelmintic drug.

Fórmula: C₂₈H₃₁N₃O₈S

Pureza: Min. 95%

Peso molecular: 569.63 g/mol

Ref: 3D-BN166808